Generalized Myasthenia Gravis (gMG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

  • Published Date : September 11, 2026
  • Updated On : November 6, 2026
  • Pages : 53

Generalized Myasthenia Gravis Unmet Needs and TPP Insights

Thelansis’s “Generalized Myasthenia Gravis (gMG) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Generalized Myasthenia Gravis Overview

Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular-junction disorder, most often involving anti-AChR or anti-MuSK antibodies. They impair nerve-to-muscle transmission, causing fluctuating weakness of eye, facial, swallowing, limb and respiratory muscles; weakness often worsens with activity and improves with rest. Severe cases may cause myasthenic crisis. Diagnosis uses antibody tests and neurophysiology. Pyridostigmine relieves symptoms; corticosteroids and steroid-sparing immunosuppressants control disease. IVIg or plasma exchange is used for serious exacerbations. Targeted options include FcRn blockers, complement inhibitors and B-cell depletion; eligibility varies by antibody subtype. In November 2026, the FDA approved gefurulimab (Klygefa) and cemdisiran (Livsayis) for adults with AChR-positive gMG; the latter is an siRNA that lowers C5. Seronegative disease remains an unmet need; monitoring for respiratory decline is essential.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Current challenges
    • Unmet needs
  • Emerging therapies
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)

Frequently asked questions